Section Arrow
Quote
GOSS.NASDAQ
- Gossamer Bio
Quotes are at least 15-min delayed:2026/02/20 04:30 EST
Pre Market
Last
 2.15
+0.04 (+1.90%)
Bid
2.15
Ask
2.16
High 2.16 
Low 2.13 
Volume 2.39K 
Regular Hours (Closed)
Last
 2.11
-0.06 (-2.76%)
Day High 
2.2263 
Prev. Close
2.17 
1-M High
2.999 
Volume 
5.21M 
Bid
2.15
Ask
2.16
Day Low
2.1 
Open
2.18 
1-M Low
2.11 
Market Cap 
502.26M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.3 
20-SMA 2.45 
50-SMA 2.84 
52-W High 3.87 
52-W Low 0.76 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.69/-0.24
Enterprise Value
704.18M
Balance Sheet
Book Value Per Share
-0.36
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
114.70M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.1967+0.0047+2.45%0.09PE
Pre Market 0.1986 +0.0019 +0.97%
IBRXImmunityBio8.61+0.07+0.82%-- 
Pre Market 8.515 -0.095 -1.10%
DRMADermata Therapeutics Inc1.93+0.65+50.78%0.08PE
Pre Market 1.61 -0.32 -16.58%
QNCXQuince Therapeutics0.1622-0.0158-8.88%-- 
Pre Market 0.1621 -0.0001 -0.06%
LIMNLiminatus Pharma Inc0.2383-0.0066-2.69%-- 
Pre Market 0.23 -0.0083 -3.48%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.